Your browser doesn't support javascript.
loading
HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions.
Gonelli, Christopher A; Khoury, Georges; Center, Rob J; Purcell, Damian F J.
Affiliation
  • Gonelli CA; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia. c.gonelli@student.unimelb.edu.au.
  • Khoury G; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia. georges.khoury@unimelb.edu.au.
  • Center RJ; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia. rob.center@burnet.edu.au.
  • Purcell DFJ; Viral Entry and Vaccines Laboratory, Disease Elimination, Burnet Institute, Melbourne, Victoria 3004, Australia. rob.center@burnet.edu.au.
Viruses ; 11(6)2019 06 02.
Article in En | MEDLINE | ID: mdl-31159488
ABSTRACT
A prophylactic vaccine eliciting both broad neutralizing antibodies (bNAbs) to the HIV-1 envelope glycoprotein (Env) and strong T cell responses would be optimal for preventing HIV-1 transmissions. Replication incompetent HIV-1 virus-like particles (VLPs) offer the opportunity to present authentic-structured, virion-associated Env to elicit bNAbs, and also stimulate T cell responses. Here, we optimize our DNA vaccine plasmids as VLP expression vectors for efficient Env incorporation and budding. The original vector that was used in human trials inefficiently produced VLPs, but maximized safety by inactivating RNA genome packaging, enzyme functions that are required for integration into the host genome, and deleting accessory proteins Vif, Vpr, and Nef. These original DNA vaccine vectors generated VLPs with incomplete protease-mediated cleavage of Gag and were irregularly sized. Mutations to restore function within the defective genes revealed that several of the reverse transcriptase (RT) deletions mediated this immature phenotype. Here, we made efficient budding, protease-processed, and mature-form VLPs that resembled infectious virions by introducing alternative mutations that completely removed the RT domain, but preserved most other safety mutations. These VLPs, either expressed from DNA vectors in vivo or purified after expression in vitro, are potentially useful immunogens that can be used to elicit antibody responses that target Env on fully infectious HIV-1 virions.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / Vaccines, DNA / Env Gene Products, Human Immunodeficiency Virus Limits: Animals / Humans Language: En Journal: Viruses Year: 2019 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / Vaccines, DNA / Env Gene Products, Human Immunodeficiency Virus Limits: Animals / Humans Language: En Journal: Viruses Year: 2019 Document type: Article Affiliation country: Australia